SC
TVTX icon

SummitTX Capital’s Travere Therapeutics TVTX Stock Holding History

SummitTX Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-112,040
Closed -$2.01M – 1011
2025
Q1 		$2.01M Buy
+112,040
New +$2.27M 0.09% 249

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SummitTX Capital's TVTX Position: Q2 2025 in Review

SummitTX Capital sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 112,040 shares — an estimated $2.01M sold.

SummitTX Capital first reported a position in TVTX in Q1 2025 and held it in 1 quarter. The position peaked at $2.01M in Q1 2025. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • SummitTX Capital reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SummitTX Capital sold 112,040 Travere Therapeutics shares in Q2 2025, an estimated $2.01M.
  • SummitTX Capital first reported a position in Travere Therapeutics in Q1 2025 and held it in 1 quarter.
  • SummitTX Capital's Travere Therapeutics position peaked at $2.01M in Q1 2025.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on SummitTX Capital's 13F filing for Q2 2025, filed 14 Aug 2025.